To determine how the breadth of the nAb response to SARS-CoV-2 variants is impacted by vaccination and prior infection, the MSD-platform ACE2 inhibition assay was carried out against the common variants of SARS-CoV-2 in both infected and previously infected individuals (Figure 2C; Supplementary Figure 2). This evidence concerns the gene ACE2 and infection.